Just saw Ascendis got FDA approval for YUVIWEL - apparently it's the first once-weekly treatment for achondroplasia in kids. That's actually pretty significant if you follow biotech stuff. They've been working on this for years with their TransCon CNP approach, basically giving continuous CNP exposure to fight the overactive FGFR3 signaling that causes achondroplasia. The approval was accelerated based on growth velocity improvements from their ApproaCH trial, which was solid enough that they published it in JAMA Pediatrics. What caught my eye was the stock reaction - ASND jumped from $233.50 to $243 in after-hours, up about 4%. They're planning to roll it out early Q2 2026 with their patient support program, plus they got a Rare Pediatric Disease Priority Review Voucher which is basically a golden ticket for future drug applications. The whole achondroplasia market has been quiet for so long, so this feels like a real breakthrough moment for these kids. Curious if other biotech companies are already working on competing treatments now.